4.3 Review

HIV-1 superinfection

期刊

CURRENT OPINION IN INFECTIOUS DISEASES
卷 25, 期 1, 页码 42-50

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QCO.0b013e32834ef5af

关键词

dual infection; HIV-1; superinfection

资金

  1. Gilead Sciences
  2. Merck Sharpe Dohme
  3. Boehringer Ingelheim
  4. ViiV Pharmaceuticals
  5. Janssen (a division of Johnson Johnson)
  6. Pfizer
  7. Abbott

向作者/读者索取更多资源

Purpose of review This review describes the nature and frequency of HIV-1 superinfection and provides advice regarding counselling of patients in accordance with national guidelines. Recent findings Recent studies have demonstrated conflicting results, from no superinfection to an incidence of over 18%. We discuss the difficulties comparing studies due to population and methodological differences. Summary HIV-infected individuals should be counselled that there is risk of superinfection at all stages of HIV, but this is unlikely to be clinically significant unless transmission of resistance occurs. The risk may be as high as the risk of new incident infection in the presence of on-going exposure.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据